Radiation is the cost of every procedure
Coronary cine is commonly acquired at 15 frames per second, and every frame is a separate X-ray pulse. Patients are exposed during each procedure; cath lab teams, procedure after procedure.
Angio-FILM (AF100) · AI software for the cath lab
CoroLogic restores low-frame-rate coronary angiography with generative AI — so cath labs can acquire at lower dose without giving up the image. Moments after each run, restored cine is back on the lab's screen, in near real time.
The cath lab trade-off
Coronary cine is commonly acquired at 15 frames per second, and every frame is a separate X-ray pulse. Patients are exposed during each procedure; cath lab teams, procedure after procedure.
Dropping cine from 15 to 7.5 fps halves the frames — and the X-ray pulses — but the motion turns choppy. Concern over image quality is why many labs keep cine at 15 fps.
Detectors, filtration and image processing have steadily lowered the dose of each frame. Frame rate is a separate lever — and software can restore the motion that fewer frames leave out.
Technology
Angio-FILM is a video frame interpolation (VFI) model built specifically for coronary angiography. It looks at two acquired frames, understands how the vessels, contrast and devices moved between them, and generates the frame that belongs in the middle. It uses latent flow matching — learning stable, direct transformation paths rather than random generation — to suppress the distortion and hallucination risks common to generative AI.












No new X-ray equipment, no extra clicks. Angio-FILM runs on a dedicated on-premise edge server between the angiography system and the review screen.
The product
A study arrives from the angiography system, contrast frames are detected, and the restored 15 fps sequence is ready for review moments later — all without anyone touching the keyboard.
Case library
Each clip shows the same run twice: the 7.5 fps acquisition on the left, and the Angio-FILM restoration to 15 fps on the right. Both play on the same clock, so the difference you see is the restoration — not playback speed.
Retrospective sample data. Patient identifiers removed; clips trimmed and compressed for web display. Shown for illustration of the research technology.
Evidence
Source: npj Digital Medicine (2026), retrospective study.
Working with CoroLogic
We're bringing Angio-FILM (AF100) to hospitals with cath labs, starting in Korea. Installations are planned from 2027 through Korea's AI Voucher program, followed from 2028 by per-case, non-reimbursed billing under the deferred new-health-technology assessment pathway.
Request a pilot assessment →Angio-FILM is available for technology partnership and licensing as a software module for angiography platforms — deployable across cath labs without new hardware.
Explore integration →A regulated, high-value market, published evidence at scale, and a team that went from spin-off to device notification, seed and TIPS in five months.
Request an overview →Real-time processing — a standalone system that restores cine as fast as the lab needs it
Ultra-low dose — restoring from even fewer acquired frames
Cine from fluoroscopy — cine-quality images from fluoro acquisition
Pediatric cardiac catheterization
Neuro-interventional angiography
Peripheral vascular intervention
Company
CoroLogic was founded on May 4, 2026 to take five years of hospital-initiated research into clinical practice. Clinicians define the problem, engineers turn it into a product, and industry veterans carry it to adoption — inside one three-person founding team.
Co-founder & CEO
Over two decades in cardiovascular intervention devices. Leads operations, investment, regulatory affairs and commercialization. MBA, Indiana University.
Co-founder & CMO
Interventional cardiologist and professor of cardiology at SNUBH. Co-inventor of Angio-FILM and principal investigator of the research program; leads clinical studies and publications.
Co-founder & CTO
11+ years building angiography systems at Siemens and Canon. Turned the research model into a deployable product; leads AI, security and clinical-grade engineering.
Newsroom
Next: BioJapan 2026, Yokohama · Oct 7–9
Selected for Korea's government-backed Tech Incubator Program for Startups (TIPS), securing R&D funding for the next 24 months to advance Angio-FILM, expand multicenter clinical research and pursue further regulatory approvals in Korea and abroad. CoroLogic was recommended by SNU Holdings, its seed investor and TIPS operator.
CoroLogic announced its first outside funding, which will go to multicenter clinical studies, product refinement, ISO 13485 certification and approvals in Korea and abroad, including FDA 510(k).
Angio-FILM was shown in the SNUBH joint pavilion at the K-Hospital + HealthTech Fair (KHF 2026), COEX, Seoul.
CEO KyungRae Hwang accepted the Good R&D Award in the medical AI category at the 12th Korea Good Company Awards.
Three months after founding, CoroLogic completed Korean MFDS Class I notification for its first software medical device.
Published in npj Digital Medicine in June, the retrospective study found that 30 physicians could not reliably tell restored angiograms from originals, with a mean absolute error of 0.18 mm in minimal lumen diameter.
A live 7.5 vs 15 fps demonstration at the Innovation Showroom drew angiography vendors, device companies and interventional cardiologists; Prof. Si-Hyuck Kang presented at the Innovation Theatre on AI and advanced imaging in coronary intervention.
The Ministry of Science and ICT program backs the path from Prof. Si-Hyuck Kang's SNUBH research to a company, including a real-time standalone processing system. Covered by more than 25 outlets.
Contact
Evaluating a pilot, exploring OEM integration, or looking at the investment case — we'd like to hear from you. We reply within one business day.